A Prospective Randomized Controlled Study of Auricular Point Acupressure to Manage Chronic Low Back Pain in Older Adults: Study Protocol

CURRENT STATUS: ACCEPTED

Chao Hsing Yeh
Johns Hopkins University School of Nursing
cyeh13@jhu.edu
Corresponding Author
ORCiD: https://orcid.org/0000-0001-5326-6660

Cuicui Li
Johns Hopkins University School of Nursing

Ronald Glick
University of Pittsburgh School of Medicine

Elizabeth A. Schlenk
University of Pittsburgh School of Nursing

Kathryn Albers
University of Pittsburgh School of Medicine

Lorna Kwai-Ping Suen
The Hong Kong Polytechnic University School of Nursing

Nada Lukkahatai
Johns Hopkins University School of Nursing

Nicole Salen
Johns Hopkins University School of Nursing

Sonaali Pandiri
Johns Hopkins University School of Nursing

Weixia Ma
Shandong Provincial Hospital

Nancy Perrin
Johns Hopkins University School of Nursing
Abstract
Background: Chronic low back pain (cLBP) is a major health problem and the most common pain condition among those 60 years of age or older in the US. Despite the development of pharmacological and nonpharmacological interventions, cLBP outcomes have not improved and disability rates continue to rise. This study aims to test auricular point acupressure (APA) as a non-invasive, nonpharmacological self-management strategy to manage cLBP and to address current shortcomings of cLBP treatment.
Methods: For this prospective randomized controlled study, participants will be randomly assigned into three groups: (1) APA (active points related to cLBP), (2) Comparison Group -1 (non-active points, unrelated to cLBP), (3) Comparison Group-2 (enhanced educational control, an educational booklet on cLBP will be given and the treatment used by participants for their cLBP will be recorded). The ecological momentary assessment smartphone app will be used to collect real-time cLBP outcomes and adherence to APA practice. Treatment and nonspecific psychological placebo effects will be measured via questionnaires for all participants. This proposed trial will evaluate the APA sustained effects for cLBP at 12-month follow-up. Monthly phone follow-up will be used to collect study outcomes. Blood will be collected during study visits at baseline, post-APA treatment, and follow-up study visits at 1-, 3-, 6-, 9- and 12-months post-completion of treatment for a total of 7 assessments. Appointments will start between 9 and 11 am to control for circadian variation in cytokine levels.
Discussion: This study is expected to provide vital information on the efficacy, sustainability, and underlying mechanism of APA on cLBP necessary for APA to gain acceptance from both healthcare providers and patients, which would provide a strong impetus for including APA as part of cLBP management in clinical and home settings.
Trial registration: NCT03589703, Registered on May 22, 2018
Keywords: Chronic low back pain, auricular point acupressure, older adults, cytokines

Background
Chronic low back pain (cLBP) is a major health problem and the most common pain condition among those 65 years of age or older in the United States (U.S.).[1] Despite the development of
pharmacological and nonpharmacological interventions, cLBP outcomes have not improved and
disability rates continue to rise.[2] Associated healthcare expenditure for cLBP is over $253 billion
annually, owing to medical care and disability-related productivity loss and wages.[3] Compared to
those in middle-age, older adults have a higher prevalence of cLBP, with longer symptom duration
and greater associated disability and depression[1, 4] and multiple medical conditions that require
multiple medications.

Pharmacotherapy is the predominant treatment for chronic pain in current U.S. medical practice for
older adults. Since the 1980s, the prescription of opioids to treat chronic pain in the U.S. has
dramatically increased.[5, 6] Compared to younger adults, older adults account for a five-time increase in hospitalizations for opioid abuse.[7] This explosive increase in opioid use for chronic
pain not only comes with significant risk, including misuse, overdose, and addiction,[8] but also brings
adverse side effects such as constipation, nausea, and somnolence.[9-11] opioid-induced
hyperlgesia,[12, 13] and cognitive dysfunction.[14, 15] Non-opioid pharmacotherapy is also
associated with a variety of adverse side effects, such as drowsiness, constipation, dry mouth,
gastrointestinal bleeding, liver and kidney toxicity, and addiction.[16, 17] Clearly, additional scalable,
safe pain management approaches must be developed to provide patients reliable, low-cost pain
relief without new side effects, prolonged treatment, or frequent visits to healthcare providers.

We will test auricular point acupressure (APA) as a non-invasive, nonpharmacological self-
management strategy to manage cLBP and to address current shortcomings of cLBP treatment. APA is
derived from auricular acupuncture, which is an invasive (use of needles) and passive treatment
(administered by a licensed practitioner). The therapeutic benefits of auricular acupuncture on pain
have been recognized by the World Health Organization (WHO).[18] In 1990, the WHO established a
standardized, internationally accepted nomenclature of ear points and their locations.[18]

Dissemination of auricular acupuncture is limited by the invasive acupuncture procedure with needles
and by the few and small sample sizes of randomized clinical trials.

**Theoretical Framework (Fig. 1).** Grounded in the biopsychosocial model of pain,[19-21] this study
framework posits that the effects of APA on clinical, psychological, and behavioral outcomes for cLBP
are mediated by inflammatory biomarkers and moderated by demographics, comorbid conditions (smoking status, obesity, and widespread pain symptoms),[22] and nonspecific psychological placebo effects (e.g., treatment beliefs,[23-26] expectations,[27, 28] and patient-provider relationships[29]). Evidence suggests that pain, anxiety,[30, 31] depression,[30, 32-35] catastrophizing,[34, 36-40] and sleep [41] are interrelated, and that catastrophizing and fear-avoidance[36, 42-44] are highly associated with cLBP. A better understanding of these factors is critical to the development of more personalized and ultimately more effective approaches to managing cLBP. The National Institutes of Health Pain Consortium Research Task Force (NIH-Pain-RTF) has proposed a set of research standards to advance research on cLBP[22] to which this study will adhere. The primary outcomes involve the personal impact of cLBP (i.e., pain intensity, pain interference, and physical function). The secondary outcomes are analgesic use, anxiety, depression, fear avoidance, catastrophizing, sleep, health-related quality of life (HRQoL), and treatment satisfaction. Comorbid conditions comprise smoking, obesity and widespread pain symptoms.[22] Relevant biological variables comprise age, gender, and body mass index (BMI). Other demographics include ethnicity and marital status. Nonspecific psychological placebo factors include treatment belief, treatment expectation, and patient-provider relationships.

Methods/design

Specific aims: Our specific aims are to (1) Determine the efficacy of APA for relieving cLBP at 1-month after completion of APA (primary endpoint) and explore monthly follow-up to 12-months to assess sustained effects of APA; (2) Determine the effects of APA on inflammatory signaling in cLBP; and (3) Examine the relationships among potential mediators and moderators that may influence the beneficial effects of APA on cLBP.

Design

For this prospective randomized controlled study, participants will be randomly assigned into three groups: (1) APA (active points related to cLBP), (2) Comparison Group (CG)-1 (non-active points, unrelated to cLBP), (3) CG-2 (enhanced educational control, an educational booklet on cLBP will be given and the treatment used by participants for their cLBP will be recorded) (Fig. 2). Participants
enrolled at CG-2 will be re-randomized into APA and CG-1 groups after 3-month follow-up assessment. For participants in APA or CG-1, blood will be collected during office visits at baseline, post-APA treatment, and follow-up study visits at 1-, 3-, 6-, 9- and 12-month post-completion of treatment for a total of 7 assessments (Fig. 2). For participants in CG-2, blood will be collected during study visits at baseline, post-APA treatment, 1-month follow-up visit, as well as visits after re-randomization (i.e., baseline, post-APA treatment, and follow-up offices visits at 1-, 3-, 6-, 9- and 12-months post-completion of treatment, for a total of 10 assessments. The EMA (Ecological momentary assessment) smartphone app will be used to collect real-time cLBP outcomes and adherence to APA practice. Treatment and nonspecific psychological placebo effects will be measured via questionnaires for all participants. Appointments will take place during the same time of day for each office visit to control for circadian variation in cytokine levels.[45, 46] All techniques have been established in our feasibility trial.[47, 48] Participants at CG-1 will have the opportunity to receive APA after completion of the study assessment.

**Recruitment.** Participants will be recruited through outpatient clinics at Johns Hopkins Hospital (JHH, including Johns Hopkins Pain Treatment Center, Johns Hopkins Community Physicians, Geriatric Medicine and General Internal Medicine Outpatient Clinics), the Community Engagement Program, social media (e.g., Craigslist), and the clinical trials.gov website. We will use the registry of the Healthy Aging Studies Unit (the National Institute on Aging-funded Johns Hopkins Older Americans Independence Center Clinical Translation and Recruitment Core). The consent will be obtained by train study coordinators.

**Study Site.** The study will be conducted at the Wald Community Nursing Center, Baltimore. The clinic has consultation rooms where face-to-face interaction with patients can occur. The clinic is staffed by nurses, nursing assistants, and reception staff.

**Study Population Inclusion and Exclusion Criteria (Table 1)**

**Table 1** Study Population Inclusion and Exclusion Criteria
| Inclusion criteria                                      | Exclusion criteria                                                                 |
|--------------------------------------------------------|-------------------------------------------------------------------------------------|
| · age 60 years or older                                 | · malignant or autoimmune diseases (e.g., rheumatoid arthritis)                     |
| · able to read and write English                        | · known acute compression fractures caused by osteoporosis, stenosis, spondylolysis, or spondylolisthesis because these may confound treatment effects or the interpretation of results |
| · cLBP that has persisted at least 3 months and pain on at least half of the days for the previous 6 months [22] | · sciatica with leg pain greater than back pain                                      |
| · average intensity of pain ≥ 4 on a 11-point numerical pain scale in the previous week | · allergy to the tape                                                                |
| · have intact cognition (Mini-Mental State Examination, MMSE > 24)                           | · use of some types of hearing aids (size may obstruct the placement of seeds)      |
| · willing to commit to 4-weekly study visits and up to 12 months follow-up.                  | · pain in other parts of the body that is more severe than the cLBP which occurs daily or almost every day with at least moderate or acute pain; neurological disorders that could interfere with reporting or confound performance on the other outcomes, tumor, Alzheimer's disease (or other cognitive illnesses), or multiple sclerosis |
| · able to apply pressure to the seeds with tapes on their ears                                |                                                                                      |

**Sample Size Justification/Study Power.** The primary outcomes are measured at 1-month post-completion of treatment. In our pilot study (i.e., pain intensity, pain interference, and physical function),[48] Cohen’s d (the effect sizes in terms of the standardized difference) ranged from 0.65 (physical function) to 1.28 (pain intensity) between the APA and the sham APA one month after intervention. Our pilot sham group (CG-1, non-reactive points) should have similar or better outcomes than CG-2 (enhanced usual care). We assume APA can sustain 90% effects at 12 months, the smallest effect size of physical function (0.65) would be 0.585 at 1 year follow-up. With a statistical power of 0.90 and alpha level of 0.05, 63 participants per group are needed to detect significant differences between the APA group and either CG-1 or CG-2 using repeated measures generalized linear model. We anticipate that approximately 30% of the enrolled participants will be lost to follow-up. Therefore, we will enroll 270 participants (90 per group). Due to high prevalence of chronic low back pain and our estimate of potential participants, we are confident to achieve this new sample size target of 270.

**Intervention: APA Treatment Protocol.** The APA protocol follows the International Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) guidelines.[49] For the APA group, ear points that will receive acupressure are within the two zones for cLBP located on the front and back of the ear and three points known for alleviating stress and pain (i.e., shenmen, sympathetic, and nervous subcortex). After the point is located, the interventionist will clean the outer ear, including the ear lobe, with 75% alcohol, then place pieces of pre-prepared tape with seeds on the participant’s ear. Points on both ears will be identified and used for treatment in the proposed study. This procedure will take 5 to 10 min. Participants will rest quietly in comfortable chairs during the process. To avoid bias, the interventionist will adhere to a scripted speech while interacting with
participants. Participants will be instructed to contact the study center immediately if any of the pieces of tape fall off their ears for replacement or if adverse effects occur. From our pilot studies, we know that patients exhibit reduced cutaneous resistance for the low back zone.[47, 48] We have found that using three pieces of tape with two seeds each is needed to sufficiently cover the low back zone on the front and back of the ear.

**Dose of Treatment.** Participants assigned to APA and CG-1 will be instructed to evenly press the tape and seeds covering each ear point without rubbing (to avoid skin damage and infection at the acupuncture point) for 3 minutes per time, three times daily (9 minutes total), even if they do not experience pain. A 2-second pause occurs between two pressings. The optimal pressure is considered to have been achieved when the participants feel localized tingling or mild discomfort. The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day. The interventionist will demonstrate the pressing technique to the participants, instructing them to apply steady pressure on the taped seeds until either mild discomfort or tingling is felt. Subsequently, the participants will do the pressing themselves. Patients will be instructed to contact the study center immediately and return for re-inspection, adjustment, and/or possible removal of the tapes if any adverse effects happen. The participants will also be instructed to not introduce any new medications or treatments for their pain during the time that they are in the intervention phase of the study. Once the study intervention phase has finished, the participants will be allowed to seek new methods of pain management as needed.

**Frequency of Treatment Visits.** The treatment duration will be 4 weeks with weekly cycles.[48] Each weekly cycle will include one office visit, 5 days of wearing the tape/seeds, and 2 days without, minimizing the risk of allergic reactions to the tape and allowing the ear points to recover and restore sensitivity prior to the next treatment. During each visit, the interventionist will place the tape/seeds on the ear points.

**Intervention Procedure.** After auricular diagnosis, the PI will write a treatment prescription (ear points for seed placement) for each participant’s APA or CG-1 by marking the points on each participant’s ear photo. The prescriptions will be saved as digital files labeled with the participant ID number, and given to the project coordinator, who will, give them to the interventionists to direct the seed placement after randomization.

**Comparison APA Group (CG-1).** For the CG-1 group, the same procedure for APA will be applied but the tapes/seeds will be placed on different points. Participants in the CG-1 will receive the APA on the five ear points, comprising mouth, stomach, duodenum, internal ear, and tonsil.[47, 48] These points are chosen for the sham APA treatment for two reasons. First, they are distinct from the zones of the ear (and the points therein) associated with the lower back, and correspond to body regions in which the participant is usually pain-free. Second, they are equivalent in number to those points used in the APA treatment group. Dose of treatment, frequency of treatment visits and intervention procedure are the same as APA treatment group.
Enhanced Educational Control Group (CG-2). The CG-2 group is essential for controlling possible placebo APA treatment effects, time, and attention. Therefore, the CG-2 will serve as the control group for any improvement over time, with education and interaction with study staff. Participants in the enhanced educational control group will be given the cLBP educational booklet published by the National Institutes of Health (https://www.niams.nih.gov/health-topics/back-pain) and visit the office weekly for assessment (i.e., blood draws and questionnaires), which is the same schedule as that for the APA and CG-1 groups. Participants enrolled in CG-2 will be re-randomized into APA and CG-1 groups at 3-month follow up.

Study Measures: We will use the minimal data set to measure cLBP outcomes (PROMIS 29 Profile), which is recommended by NIH-Pain-RTF.[22] Participants can complete the data set within 7-10 minutes.[22] Mini-Mental State Examination[50] will be used to screen for cognitive function. We will also include measures of HRQoL, satisfaction, treatment beliefs and expectations, sleep, relaxation effects, catastrophizing and fear/avoidance, and placebo effects (Table 1). A paperless data entry system, installed in iPads, will be used to allow data to be directly entered into the database.

Table 2 Summary of Study Measures

| Construct | Specific Measure | # Items | Reliability & Validity | Time |
|-----------|-----------------|---------|------------------------|------|
| SCREENING | Mini-Mental State Examination | Good[50] | † |
| PRIMARY OUTCOMES: Pain intensity, Pain Interference, Physical Function | Minimal Data Set | 4 | Good[22] | †, ‡ |
| SECONDARY OUTCOMES | Analgesic Use | Quantification Score Version III | Objective[51] | †, ‡ |
| | HRQoL | Health-Related Quality of Life | 36 | High[52] | † |
| | Satisfaction | Treatment Satisfaction | 12 | Good[47, 48] | 4wk 0 |
| Psychological | Anxiety, Depression | Minimal Data Set | 8 | Good[22] | † |
| | Fear/Avoidance | Fear Avoidance Beliefs | 16 | Good[53] | † |
| | Catastrophizing | Pain Catastrophizing Scale | 13 | Good[54] | † |
| Behavioral | Sleep | Minimal Data Set | | Good[22] | |
| | Relaxation | Relaxation Response | 1 | Pilot study | † |
| MODERATING VARIABLES: Comorbidity, Demographics | Minimal Data Set | | | Good[22] | Basel |
| NONSPECIFIC PSYCHOLOGICAL PLACEBO EFFECTS | Expectation, Belief | Treatment Expectation | 2 | Good[47, 48] | Basel |
| | Relationship | Patient-Provider Relationship | 7 | Good[55] | † |

EMA; † Baseline, post completion of treatment, monthly follow-up for 3 months

The ecological momentary assessment (EMA) is a data collection method that is programmed in the smartphone app so that the pain intensity data can be collected in real time. We have pilot-tested the smartphone app to collect data on participants’ adherence to the APA treatment and real-time pain...
outcomes.[56] It was reported as easy to use and minimized recall bias.[56] Each participant will be provided a smartphone and charger and instructed to use the EMA daily and charge the smartphone each evening. Our EMA app[56] has been revised and customized to enhance user-friendliness, enlarged font size screen, and adjust volume control to optimize use for older adults. The data collected through EMA will be used to calculate participants’ (1) frequency and duration of APA practice, and (2) medication use and clinical outcomes (i.e., pain intensity, pain interference, and physical function), each measured by one question. The EMA app includes two surveys addressing: (1) random EMA of the real-time outcomes (pain intensity, pain interference, and physical function) and (2) time-contingent EMA for the adherence of APA practice and analgesic use, which will be prompted according to the participant’s schedule. The random EMA survey is programmed to deliver one random prompt per day during waking hours commensurate with each participant’s schedule. The four items addressing momentary pain/function level can be completed within 1 minute. Time-contingent EMA survey entries of APA practice and analgesic use will take under 2 min to complete. Adherence will be calculated by the proportion of EMA completed and proportion of days in which APA practice goals are met. EMA questions will be presented one at a time on the screen. Participants will respond to each question by using the touch screen to move the cursor forward and back and then exit the questionnaire. EMA data will automatically upload to the project website in real time via an economical cellphone carrier data plan, and it will be evaluated every 72 hours to determine usage. The smartphones selected are designed to support the Android or iPhone operating system separately and feature a large high-resolution color liquid crystal display (LCD) touch screen and non-volatile memory to avoid data loss in the event the battery discharges. Participants who do not enter EMA data for more than 2 days will be contacted to determine the reason, will be assisted in resolving any problems, and will then be encouraged to resume EMA recording.

**Blood Sample Collection/Testing for Biomarkers.** We will follow the protocol from our pilot studies for collecting and analyzing blood samples.[57, 58] A 15 mL blood sample will be drawn at baseline, 4 weekly office visits during APA treatment, and follow-up at 1-, 3-, 6-, 9- and 12-months post-completion of APA (10 time points). Blood samples will be collected using standard phlebotomy procedures and processed immediately for serum collection (coagulation and serum separation by centrifugation). Serum will be stored at -80 °C at the Johns Hopkins University (JHU) School of Nursing. All specimens will be multiplexed and duplicated in assays and analyzed using Bio-Plex Manager software in the Immune Monitoring Core at the Johns Hopkins Oncology Center, which has extensive expertise in multiplex assays. The serum levels of IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, IFN-γ, TNF-α, CGRP, and TGF-β will be measured using a multiplex bead-based immunofluorescence assay performed by a blinded technician (Luminex-200 system, Version IS, Luminex, Austin, TX). A five-parameter regression formula will be used to calculate the sample concentrations from the standard curve. The quantification of biomarkers will be performed in duplicate to verify the results. These assays typically exhibit high precision and reproducibility (i.e., 84.5% sensitivity, 98% specificity; 92% of the patients in the active disease group correctly classified from a cross-validation serum set).[59]

**Randomization:** After baseline data have been collected, all eligible participants will be randomized into three groups. The randomization process will be performed by a systems analyst with the use of statistical software equipped with a random-number generator to create a list of group assignments before the study recruitment begins. This procedure will allow real-time randomization to occur immediately after baseline assessments. Randomization will occur in blocks of three or six, with
assignments based on the specific number of expected eligible participants and divided equally between the three groups. The program locates the first unassigned record in the randomization list and assigns the participant to the group designated in that record. Participant identifier and date are written on the record.

**Blinding:** Participants cannot be masked to the enhanced educational group to which they have been allocated because of the nature of the intervention. Participants at APA and CG-1 groups will be blinded regarding group assignment and will be evaluated for the treatment allocation after the first APA treatment, not at the end of the completed treatments to avoid bias due to the perceived treatment effects based on intelligent guessing. The *interventionists* will be blinded because (1) two interventionists will be trained; one for the APA and one for the CG-1 group, and (2) fidelity testing regularly implemented. The PI and Co-Is will be blinded regarding group assignment and will not contact or interact with the participants during the intervention. The *data collector* for outcome assessments will be blinded since there will be no seeds placed on the ears when the data are collected. *Data analysis* will be blinded because the information of the group assignment will be withheld and we will also use an independent statistician for analysis. Group allocation will be known by a minimum number of study personnel.

**Fidelity of Intervention:** Fidelity of the interventionists will be assured and assessed by four methods: (1) Interventionists will demonstrate their proficiency with written and oral examinations and will be observed and mentored during training. (2) The interventionists will take photos of every participant’s ear after the seeds have been placed and the photos will be sent to the PI for comparison to her treatment prescription to maintain at least 95% accuracy for the first 20 participants, and will then be randomly selected to check for accuracy monthly during the study. The inter-rater reliability (Kappa) of point identification accuracy between the PI and the interventionists will be established. If Kappa scores are less than 0.8, further training will occur. (3) The PI will develop a schedule of random visits with interventionists to observe their adherence to protocol in real-time. (4) To avoid any bias caused by the interventionists, they will be taught to adhere to a scripted speech during interaction with participants.
**Data Management:** We will use a paperless data entry system with password-protected access to allow data to be entered directly into the database. All measures for office visits will be in electronic form with customized data entry, and a direct data entry system will be installed on iPads. Data will be collected during one-on-one sessions with participants, eliminating the need for and cost of double data entry using paper forms, and decreasing missing and incorrect data entries. All of the data and uploaded EMA data will be encrypted and stored in a Microsoft SQL server on the JHU project website with a date/time stamp. All participants will be assigned unique study identifiers that will appear on all data collection instruments, documents, and files used in statistical analysis and manuscript preparation. Personal information is needed for tracking informed consent, which will be stored separately from other data and accessible only to select team members. No participant's information will be released. Serum for biomarker analysis will be labeled with study ID and date of phlebotomy and kept at -80 °C in a locked room.

**Treatment of Missing Data:** With the use of direct data entry, we expect to minimize missing data. We will obtain reasons for study dropout so that we can assess the missing data mechanism. If the assumption of missing at random (MAR) is reasonable, likelihood-based methods that ignore the response mechanism will be appropriate. If the probability of missingness depends on the unobserved data even after the observed data are conditioned (i.e., non-ignorable missingness), we will consider both selection models and pattern-mixture models to guide our chosen model. The effect of our assumptions on inferences regarding the missing mechanism will be assessed by using sensitivity analyses.

**Data Analysis Plan:** Data will be audited by an independent safety officer annually and analyzed in phases, with initial screening of data followed by primary analysis to address each research aim. The *intent-to-treat* approach, with inclusion of all participants randomly assigned to groups—regardless of adherence, treatment received, or withdrawal—will be used to address our specific aims. Adherence to the assigned group will be monitored and examined in exploratory analyses. All statistical analyses will be preceded by detailed descriptive summaries. Violations of assumptions underlying planned methods will be checked, and appropriate data transformation will be performed,
if needed. Data analyses will be conducted using Statistical Analysis System (SAS Institute Inc., Cary, NC).

In order to examine Aim 1 to determine the efficacy of APA for cLBP at one month post treatment, we will use a general linear mixed model (GLM) to construct a multilevel model for comparing the differences in the change in the outcomes from baseline to one month among the three groups. The group-by-time interaction is the main parameter of interest. For Aim 2 to evaluate the effect of APA on biomarkers, the analytical strategies for Specific Aim 1 will be used. Outcomes at one month post treatment will be examined using each biomarker individually and two latent variables with pre-defined biomarkers within the groups of pro- and anti-inflammatory biomarkers. For Aim 3 to examine whether or not demographics, comorbid conditions, and placebo effects moderate the relationship between APA treatment on primary and secondary outcomes, the previously described regression models in Specific Aim 1, which include the main effect terms for the intervention or group, will be expanded to include the main effect terms for moderators and the three-way interaction terms between group, time, and moderators. Data from the smartphone EMA app will be analyzed per our published methods and the following analysis plan.\[56, 65\] Adherence to APA practice, medication use, and real-time cLBP outcomes will be calculated and compared among groups using MANOVA or Chi-square test to compare the differences between groups over time. Joinpoint regression \[66\] will be used to estimate the linear trend of improvement in percentages of outcome score over time. This strategy will help analyze trends with different lines connected together at some joinpoints based on a log linear regression: \[\ln \text{(percentage)} = \beta_0 + \beta_1 \times \text{(calendar day)}\]. Each joinpoint represents a significant change in the trend slope; the best number of joinpoints will be determined by a permutation test.

**Discussion**

There are some potential challenges for this study. Adherence is one of the challenges. EMA data will be checked every 72 hours to determine usage. Participants who fail to respond to EMA prompts for more than 2 days will be contacted to determine the reason for not doing so. Fidelity of APA is a challenge, too. Ear photos after seed placement will be taken and will be evaluated by the PI’s
marked photos to ensure the competency to administer APA with fidelity. Further training will be provided if necessary. We are aware that reducing participant burden is important.

Other challenges include recruitment and dropout. Recruitment will be monitored closely. We have the support of a cohesive team of experienced co-Is who are recognized in their areas of knowledge and will contribute their complementary expertise to this project. Changes in recruitment procedure will be made if lower-than-expected recruitment occurs. The changes to the protocol are waiting to be approved by the IRB. We will provide participants with free parking or transportation to facilitate coming to sessions, and reimburse them for their time. We will also call/reschedule when a treatment session is missed. Participants in the CGs will have opportunities to receive APA after they complete the study. For participants who decline further treatment or are unable to come in for follow-up assessments, we will contact them to complete questionnaire data by phone. Although we did not have complaints of excessive burden in the pilot study and observed a 90% retention rate after receiving the first APA treatment, we have further minimized burden with the smartphone to collect the daily data.

This study will provide vital information on the efficacy, sustainability, and underlying mechanism of APA on cLBP necessary for APA to gain acceptance from both healthcare providers and patients, which would provide a strong impetus for including APA as part of cLBP management in clinical and home settings.

**Trial status and publication plan**

Protocol version number and date: NCT03320200 July 2018. Recruitment begun in March 2019. Recruitment will be completed in February 2023. After recruitment completion, data will be analyzed and published in peer review journals or presentations at professional conferences, then the final report will be prepared and published.

**Abbreviations**

cLBP: Chronic low back pain; APA: Auricular point acupressure; CG: Comparison Group; EMA: Ecological momentary assessment; CDC: The Centers for Disease Control and Prevention; U.S.: United States; WHO: World Health Organization; NIH-Pain-RTF: National Institutes of Health Pain
Consortium Research Task Force; CGRP: Calcitonin gene-related peptide; HRQoL: Health-Related Quality of Life; BMI: Body Mass Index; JHH: Johns Hopkins Hospital; JHU: Johns Hopkins University; STRICTA: Standards for Reporting Interventions in Clinical Trials of Acupuncture; PI: Principal investigator; Co-I: Co-Investigator; MAR: Missing at random; SAS: Statistical Analysis System; GLM: General linear mixed model; LCD: liquid crystal display.

Declarations

Ethics approval and consent to participate: This study protocol has received ethical approval by Johns Hopkins Medicine Institutional Review Board, Baltimore Maryland (IRB00175409), June 28 2018. The aims and potential risks of this study will be completely explained to the participants. Before participation, all participants need to provide written informed consent. On the consent form, participants will also be asked for their permission to grant the research team the authority to share data and biospecimens with relevant people from the universities taking part in the research and other regulatory authorities, where relevant.

Consent for publication: Not Applicable.

Availability of data and materials: Not applicable.

Competing interests: Not applicable.

Funding: Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Number R01AG056587. The study funder doesn’t play a role in study design, data collection and management, and manuscript writing publication.

Availability of data and materials: The datasets analyzed will be available from the corresponding author on request.

Authors' contributions: Yeh, Christo, Glick, Morone, Schlenk, Albers, Suen, and Perrin designed this protocol study. Yeh, Li, Lukahatai, Salen and Sonaali have contributed to writing of this manuscript. All named authors adhere to the authorship guidelines of Trials. All authors have agreed to publication.

Acknowledgements: Not applicable

References
1. Knauer SR, Freburger JK, Carey TS. Chronic low back pain among older adults: A population-based perspective. Journal of Aging and Health. 2010;22(8):1213-34.

2. Deyo RA, et al. Overtreating chronic back pain: time to back off? J Am Board Fam Med. 2009;22(1):62-8.

3. Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington (DC): National Academies Press (US); 2011.

4. Makris UE, et al. Restricting back pain and subsequent mobility disability in community-living older persons. J Am Geriatr Soc. 2014;62(11):2142-7.

5. NIDA. Prescription Opioids and Heroin. National Institute on Drug Abuse. 2018. https://www.drugabuse.gov/publications/research-reports/prescription-opioids-heroin. Accessed 5 Dec. 2019.

6. Chou R, Deyo R, Devine B, Hansen R, Sullivan S, Jarvik JG, Blazina I, Dana T, Bougatsos C, Turner J. The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain. Evid Rep Technol Assess (Full Rep). 2014;(218):1-219.

7. Okie S. A Flood of Opioids, a Rising Tide of Deaths. New England Journal of Medicine. 2010;363(21):1981-1985.

8. Deyo RA, Von Korff M, Duhrkoop D. Opioids for low back pain. Bmj. 2015; 350:g6380.

9. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician 2008; 11(2 Suppl):S105-20.

10. Candiotti KA, Gitlin MC. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Curr Med Res Opin. 2010;26(7):1677-84.

11. Poulsen JL, et al. Evolving paradigms in the treatment of opioid-induced bowel
dysfunction. Therap Adv Gastroenterol. 2015;8(6):360-72.

12. Carullo V, Fitz-James I, Delphin E. Opioid-Induced Hyperalgesia: A Diagnostic Dilemma. J Pain Palliat Care Pharmacother. 2015;29(4):378-84.

13. Chen L, et al. Clinical interpretation of opioid tolerance versus opioid-induced hyperalgesia. J Opioid Manag. 2014;10(6): 383-93.

14. Dublin S, et al. Prescription Opioids and Risk of Dementia or Cognitive Decline: A Prospective Cohort Study. J Am Geriatr Soc. 2015;63(8):1519-26.

15. Pergolizzi J, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8(4):287-313.

16. Malanga G, Wolff E. Evidence-informed management of chronic low back pain with nonsteroidal anti-inflammatory drugs, muscle relaxants, and simple analgesics. The Spine Journal. 2008;8(1):173-184.

17. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11): 2227-46.

18. Working Group on Auricular Acupuncture Nomenclature (1990: Lyon, France) & World Health Organization. Traditional Medicine Unit. (1991). Report on the Working Group on Auricular Acupuncture Nomenclature, Lyon, France, 28-30 November 1990. World Health Organization. https://apps.who.int/iris/handle/10665/60870

19. Gatchel RJ, et al. The biopsychosocial approach to chronic pain: Scientific advances and future directions. Psychological Bulletin. 2007;133(4):581-624.

20. Lumley MA, et al. Pain and emotion: A biopsychosocial review of recent research. Journal of Clinical Psychology. 2011;67(9):942-68.

21. Campbell CM, Edwards RR. Mind-body interactions in pain: The neurophysiology of
anxious and catastrophic pain-related thoughts. Translational Research. 2009;153(3):97-101.

22. Deyo RA, et al. Report of the NIH task force on research standards for chronic low back pain. The Journal of Pain. 2014;15(6):569-585.

23. Lundeberg T, Lund I. Acupuncture for preconditioning of expectancy and/or Pavlovian extinction. Acupuncture in Medicine. 2008;26(4):234-8.

24. Lundeberg T, Lund I, Naslund J. Acupuncture - Self-appraisal and the reward system. Acupuncture Medicine. 2007;25(3):87-99.

25. Furlan AD, et al. A systematic review and meta-analysis of efficacy, cost-effectiveness, and safety of selected complementary and alternative medicine for neck and low-back pain. Evid Based Complement Alternat Med. 2012;2012:953139.

26. Vickers AJ, et al. Individual patient data meta-analysis of acupuncture for chronic pain: protocol of the Acupuncture Trialists' Collaboration. Trials. 2010;11:90.

27. Hsu C, et al. New perspectives on patient expectations of treatment outcomes: Results from qualitative interviews with patients seeking complementary and alternative medicine treatments for chronic low back pain. BMC Complement Altern Med. 2014;14(276).

28. Schafer LM, et al. Complementary and alternative medicine (CAM) providers' views of chronic low back pain patients' expectations of CAM therapies: a qualitative study. BMC Complement Altern Med. 2012;12:234.

29. Lind BK, et al. The role of alternative medical providers for the outpatient treatment of insured patients with back pain. Spine. 2005;30(12):1454-1459.

30. Berde C, Wolfe J. Pain, anxiety, distress, and suffering: interrelated, but not interchangeable. Journal of Pediatrics. 2003;142(4):361-3.

31. Moix J, et al. Catastrophizing, state anxiety, anger, and depressive symptoms do not
correlate with disability when variations of trait anxiety are taken into account. A study of chronic low back pain patients treated in Spanish pain units. Pain Medicine. 2011;12(7):1008-1017.

32. Bonnewyn A, et al. Pain and depression in older people: Comorbidity and patterns of help seeking. Journal of Affective Disorders. 2009;117(3):193-196.

33. Denkinger MD, et al. Multisite pain, pain frequency and pain severity are associated with depression in older adults: results from the ActiFE Ulm study. Age Ageing. 2014;43(4):510-514.

34. Edwards RR, et al. Pain, catastrophizing, and depression in the rheumatic diseases. Nat Rev Rheumatol. 2011;7(4):216-224.

35. Vines SW, et al. The relationship between chronic pain, immune function, depression, and health behaviors. Biological Research for Nursing. 2003;5(1):18-29.

36. Buer N, Linton SJ. Fear-avoidance beliefs and catastrophizing: Occurrence and risk factor in back pain and ADL in the general population. Pain. 2002;99(3):485-491.

37. Cassidy EL, et al. Mindfulness, functioning and catastrophizing after multidisciplinary pain management for chronic low back pain. Pain. 2012;153(3):644-650.

38. Edwards RR, et al. Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. Arthritis Care and Research 2006;55(2):325-332.

39. Picavet HSJ, Vlaeyen JWS, Schouten JSAG. Pain catastrophizing and kinesiophobia: predictors of chronic low back pain. American Journal of Epidemiology. 2002;156(11):1028-1034.

40. Severeijns R, et al. Pain catastrophizing is associated with health indices in musculoskeletal pain: A cross-sectional study in the Dutch community. Health Psychology. 2004;23(1):49-57.

41. Yeh CH, Suen LK, Shen J, Chien LC, Liang Z, Glick RM, Morone NE, Chasens ER.
42. Changes in Sleep With Auricular Point Acupressure for Chronic Low Back Pain.

43. Behav Sleep Med. 2016;14(3):279-94.

44. Basler HD, et al. *Fear-avoidance beliefs, physical activity, and disability in elderly individuals with chronic low back pain and healthy controls*. Clinical Journal of Pain. 2008;24(7):604-10.

45. Wertli MM, et al. *The role of fear avoidance beliefs as a prognostic factor for outcome in patients with nonspecific low back pain: a systematic review*. Spine J. 2014;14(5):816-36.e4.

46. Wideman TH, Adams H, Sullivan MJL. *A prospective sequential analysis of the fear-avoidance model of pain*. Pain. 2009;145(1-2):45-51.

47. Keller M, et al. *A circadian clock in macrophages controls inflammatory immune responses*. Proc Natl Acad Sci U S A. 2009;106(50):21407-12.

48. Fonken LK, et al. *Microglia inflammatory responses are controlled by an intrinsic circadian clock*. Brain Behav Immun. 2015;45:171-9.

49. Yeh CH, Chien LC, Balaban D, Sponberg R, Primavera J, Morone NE, Glick R, Albers KM, Cohen SM, Ren D, Huang LC, Suen LC. A randomized clinical trial of auricular point acupressure for chronic low back pain: a feasibility study. Evid Based Complement Alternat Med. 2013;2013:196978.

50. Yeh CH, et al. *Auricular point acupressure to manage chronic low back pain in older adults: A randomized controlled pilot study*. Evidence-Based Complementary and Alternative Medicine. 2014;Article ID 375173.

51. MacPherson H, et al. *Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): Extending the CONSORT statement*. PLoS Med. 2010;7(6):e1000261.

52. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". *A practical method for
grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12(3):189-98.

53. Harden RN, et al. Medication quantification scale Version III: Update in medication classes and revised detriment weights by survey of American Pain Society physicians. The Journal of Pain. 2005;6(6):364-371.

54. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Medical Care.1992;30(6):473-83.

55. Waddell G, et al. A Fear-avoidance beliefs questionnaire (FABQ) and the role of fear-avoidance beliefs in chronic low back pain and disability. Pain. 1993;52(2):157-168.

56. Sullivan MJL, Bishop SR, Pivik J. The pain catastrophizing scale: Development and validation. Psychological Assessment. 1995;7(4):524-532.

57. Safran DG, et al. Measuring patients' experiences with individual primary care physicians. Journal of General Internal Medicine. 2006;21(1):13-21.

58. Lin WC, Burke L, Schlenk EA, Yeh CH. Use of an Ecological Momentary Assessment Application to Assess the Effects of Auricular Point Acupressure for Chronic Low Back Pain. Comput Inform Nurs. 2018;doi: 10.1097/CIN.0000000000000478.

59. Yeh CH, et al. Function of auricular point acupressure in inducing changes in inflammatory cytokines during chronic low back pain: A pilot study. Medical Acupuncture. 2014;26(1):31-39.

60. Lin WC, Yeh CH, Chien LC, Morone NE, Glick RM, Albers KM. The Anti-Inflammatory Actions of Auricular Point Acupressure for Chronic Low Back Pain. Evid Based Complement Alternat Med. 2015;2015:103570.

61. Linkov F, et al. Early detection of head and neck cancer: Development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiology, Biomarkers & Prevention. 2007;16(1):102-7.
62. Little R, Rubin D. *Statistical Analysis with Missing Data*. 2nd ed. New York: Wiley; 2002.

63. Verbeke G, Molenberghs G. *Linear Mixed Models for Longitudinal Data*. 1st ed. New York: Springer; 2000.

64. Newell DJ. *Intention-to-treat analysis: Implications for quantitative and qualitative research*. International Journal of Epidemiology. 1992;21(5):837-41.

65. Wertz R. *Intention to treat: Once randomized, always analyzed*. Clinical Aphasiology. 1995;23:57-64.

66. Heritier SR, Gebski VJ, Keech AC. Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust. 2003;179(8):438-40.

67. Yeh CH, et al. *Day-to-day changes of auricular point acupressure to manage chronic low back pain: A 29-day randomized control study*. Pain Medicine. 2015;16(10):1857-69.

68. Joinpoint Regression Program, *Statistical Methodology and Applications Branch, Surveillance Research Program*. 2019, National Cancer Institute. https://surveillance.cancer.gov/joinpoint/. Accessed 12 Dec 2019.

**Figures**
Figure 1
Framework of APA Effects for cLBP

Figure 2
Overview of Research Design
## Figure 3

The schedule of enrolment, interventions, and assessments.

### Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

SPIRIT_Fillable-checklist-12132019.doc